ReviewCancer management and research2017
Management of malignant pleural effusion: challenges and solutions.
Review in Cancer management and research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06959173 (Organoid-guided Personalized Treatment of Pleural Effusion), which is not on this map. Cited by 66 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Organoid-guided Personalized Treatment of Pleural Effusion
Who cites it
66 citing papers in PubMed, 3 syntheses or guidelines pooled it, 114 citations in OpenAlex.
- [A Meta-Analysis of Efficacy and Adverse Effects of Lobaplatin and Cisplatin in the Treatment of Malignant Pleural Effusion].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2019Pooled it
- Pooled it
- Pooled it
- Ultrasound Techniques for Suspected Malignant Pleural Effusion and Nonexpandable Lung.CHEST pulmonary · 2026Review
- Safety and Efficacy of Single-Stage Synchronous Bilateral VATS Talc Poudrage for Malignant Pleural Effusion.Cancers · 2026Article
- Clinical characteristics, treatment response, and survival outcomes in melanoma patients with cavity carcinomatosis: A retrospective analysis.International journal of cancer · 2026Article
- Development and multicenter validation of a predictive model for malignant pleural effusion recurrence.iScience · 2026Article
- Turning Fluids into Data for Precision Oncology: A Multidisciplinary Tumor Board Approach to Malignant Pleural Effusions.Biomedicines · 2026Review
- Pathobiology and clinical significance of malignant pleural effusions.EMBO molecular medicine · 2026Review
- Deep learning for malignancy and tumor origin prediction using cytology or histopathology whole slide images.NPJ digital medicine · 2026Article
- Fluid-Derived Organoids from Pleural Effusion and Ascites: Emerging Models for Drug Resistance and Personalized Oncology.Journal of Cancer · 2026Review
- Re-evaluating breast malignant pleural effusion: toward evidence-based, precision-aligned care with organoids.Frontiers in bioengineering and biotechnology · 2026Article
- Diagnostic Yield of Malignant Pleural Effusion in Various Primary and Metastatic Cancers: Insights Across Cancer Subtypes.Pulmonary medicine · 2026Article
- The impact of preoperative percutaneous transthoracic needle biopsy on pleural recurrence in clinically early-stage non-small cell lung cancer.Journal of thoracic disease · 2025Article
- Malignant Pleural Effusion: Palliative Managements and Indication for Pleurodesis Based on Survival Scores.Journal of surgical oncology · 2025Review
- Development and validation of a machine learning-based nomogram for predicting prognosis in lung cancer patients with malignant pleural effusion.Scientific reports · 2025Article
- Prognostic factors and treatment outcomes in EGFR-mutated NSCLC with malignant pleural effusion: focus on intrathoracic chemotherapy and EGFR-TKI therapy.Frontiers in oncology · 2025Article
- Investigation of the Prevalence of Chronic Pulmonary Effusion Causes and Response to Treatment (Pleurodesis) in Patients.The open respiratory medicine journal · 2025Article
- Application of the metagenomic next-generation sequencing technology to identify the causes of pleural effusion.Frontiers in medicine · 2025Article
- A patient-centred approach to malignant pleural effusion.European clinical respiratory journal · 2025Review
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
Abstract
Malignant pleural effusion (MPE) is a sign of advanced cancer and is associated with significant symptom burden and mortality. To date, management has been palliative in nature with a focus on draining the pleural space, with therapies aimed at preventing recurrence or providing intermittent drainage through indwelling catheters. Given that patients with MPEs are heterogeneous with respect to their cancer type and response to systemic therapy, functional status, and pleural milieu, response to MPE therapy is also heterogeneous and difficult to predict. Furthermore, the impact of therapies on important patient outcomes has only recently been evaluated consistently in clinical trials and cohort studies. In this review, we examine patient outcomes that have been studied to date, address the question of which are most important for managing patients, and review the literature related to the expected value for money (cost-effectiveness) of indwelling pleural catheters relative to traditionally recommended approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.